Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISE FLUIDS: Fluid or Vasopressors in Emergency Department Sepsis
NCT04569942Phase 3Active, not recruiting
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
- Start
- Oct 2021
- Primary completion
- Feb 2026
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in septic shock (2 arms), sponsored by Australian and New Zealand Intensive Care Research Centre. Primary endpoint: Days alive and out of hospital at 90 days. Started Oct 2021; status: active, not recruiting.
02
Conditions
septic shock
Beyond the preview
Go deeper on NCT04569942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569942.